MTNB Matinas BioPharma Holdings Inc
Price (delayed)
$0.5585
Market cap
$2.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.85
Enterprise value
-$4.38M
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has
Highlights
Matinas BioPharma Holdings's debt has decreased by 17% YoY and by 5% QoQ
The EPS has grown by 10% from the previous quarter and by 10% YoY
The gross profit has dropped by 100% year-on-year
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
Key stats
What are the main financial stats of MTNB
Market
Valuations
Earnings
Shares outstanding
5.09M
Market cap
$2.84M
Enterprise value
-$4.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.18
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$22.01M
Net income
-$21.13M
EBIT
-$21.13M
EBITDA
-$20.17M
Free cash flow
-$16.95M
Per share
Balance sheet
Liquidity
EPS
-$4.85
EPS diluted
-$4.85
Free cash flow per share
-$3.37
Book value per share
$3.15
Revenue per share
$0
TBVPS
$3.82
Total assets
$20.58M
Total liabilities
$4.8M
Debt
$3.07M
Equity
$15.78M
Working capital
$9.62M
Debt to equity
0.19
Current ratio
5.53
Quick ratio
5.11
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-94.3%
Return on equity
-123.1%
Return on invested capital
-124.2%
Return on capital employed
-114.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MTNB stock price
How has the Matinas BioPharma Holdings stock price performed over time
Intraday
-2.02%
1 week
-2.15%
1 month
-3.67%
1 year
-96.81%
YTD
9.51%
QTD
7.4%
Financial performance
How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.01M
Net income
-$21.13M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
The company's net income rose by 8% QoQ
The operating income has grown by 7% from the previous quarter and by 6% YoY
Growth
What is Matinas BioPharma Holdings's growth rate over time
Valuation
What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
0.18
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 10% from the previous quarter and by 10% YoY
The stock's price to book (P/B) is 94% less than its 5-year quarterly average of 3.0 and 93% less than its last 4 quarters average of 2.4
The company's equity fell by 32% YoY and by 17% QoQ
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
Efficiency
How efficient is Matinas BioPharma Holdings business performance
The ROE has dropped by 74% year-on-year and by 2.2% since the previous quarter
Matinas BioPharma Holdings's ROIC has plunged by 70% YoY and by 9% from the previous quarter
The return on assets has dropped by 63% year-on-year
Dividends
What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MTNB.
Financial health
How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets has decreased by 31% YoY and by 16% QoQ
MTNB's total liabilities is down by 28% year-on-year and by 9% since the previous quarter
Matinas BioPharma Holdings's debt is 81% lower than its equity
The company's equity fell by 32% YoY and by 17% QoQ
The company's debt to equity rose by 19% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.